aspartic acid has been researched along with Dementia in 49 studies
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.
aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent
L-aspartic acid : The L-enantiomer of aspartic acid.
Dementia: An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of study was to search for new biomarkers with a magnetic resonance technique to identify the early stages of dementia, induced by D-galactose, and evaluate Simvastatin therapy." | 7.81 | Neuronal marker recovery after Simvastatin treatment in dementia in the rat brain: in vivo magnetic resonance study. ( Dubovický, M; Kašparová, S; Kucharská, J; Liptaj, T; Lipták, B; Sumbalová, Z; Szomolányi, P; Trattnig, S; Tušková, R; Uličná, O; Vančová, O, 2015) |
| "The purpose of this study was to determine cerebral myo-inositol (mI) in adults with Down syndrome (DS), and to trace the chronobiology of DS to Alzheimer disease (AD)." | 7.69 | Role of increased cerebral myo-inositol in the dementia of Down syndrome. ( Ross, BD; Shonk, T, 1995) |
| "Neurodegenerative dementias are characterized by elevated myoinositol and decreased N-acetylaspartate (NAA) levels." | 4.89 | Magnetic resonance spectroscopy in common dementias. ( Kantarci, K, 2013) |
| "The aim of study was to search for new biomarkers with a magnetic resonance technique to identify the early stages of dementia, induced by D-galactose, and evaluate Simvastatin therapy." | 3.81 | Neuronal marker recovery after Simvastatin treatment in dementia in the rat brain: in vivo magnetic resonance study. ( Dubovický, M; Kašparová, S; Kucharská, J; Liptaj, T; Lipták, B; Sumbalová, Z; Szomolányi, P; Trattnig, S; Tušková, R; Uličná, O; Vančová, O, 2015) |
| " Myo-inositol (mI), whose transporter gene is located on chromosome 21, has been associated with dementia in the non-DS population; however, nobody has contrasted brain mI in DS with (DS+) and without (DS-) dementia to other non-DS groups." | 3.77 | Down syndrome with and without dementia: an in vivo proton Magnetic Resonance Spectroscopy study with implications for Alzheimer's disease. ( Archer, N; Beacher, F; Daly, E; Foy, CML; Lamar, M; Lovestone, S; Morris, RG; Murphy, DGM; Murphy, KC; Poppe, M; Prasher, V; Simmons, A, 2011) |
| " Although changes in myo-inositol and creatine occur in the early stages of AD, abnormalities of N-acetyl aspartate do not occur in mild AD but progressively change with dementia severity." | 3.71 | Brain metabolite concentration and dementia severity in Alzheimer's disease: a (1)H MRS study. ( Alexander, GE; Chang, L; Huang, W; Krasuski, JS; Rapoport, SI; Schapiro, MB; Shetty, HU, 2001) |
| "The purpose of this study was to determine cerebral myo-inositol (mI) in adults with Down syndrome (DS), and to trace the chronobiology of DS to Alzheimer disease (AD)." | 3.69 | Role of increased cerebral myo-inositol in the dementia of Down syndrome. ( Ross, BD; Shonk, T, 1995) |
| "To evaluate cerebral biochemical abnormalities in patients with frontotemporal dementia and Alzheimer disease and to determine whether proton (hydrogen-1) magnetic resonance (MR) spectroscopy can help differentiate among these two patient groups and healthy (control) subjects." | 3.69 | Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy. ( Chang, L; Ernst, T; Mehringer, CM; Melchor, R, 1997) |
| "Dementia was an independent predictor of metabolite values." | 2.73 | Magnetic resonance spectroscopy performance for detection of dementia, Alzheimer's disease and mild cognitive impairment in a community-based survey. ( Antúnez, C; Carles, R; Fortuna, L; García Santos, JM; Gavrila, D; Jiménez Veiga, J; Navarro, C; Parrilla, G; Salmerón, D; Tormo, MJ; Torres del Río, S, 2008) |
| "We validated the utility of SPM8 plus DARTEL (VSRAD) combined with magnetic resonance spectroscopy (1H MRS) as an adjunct screening technique for dementia due to Alzheimer's disease (AD)." | 1.40 | Utility of SPM8 plus DARTEL (VSRAD) combined with magnetic resonance spectroscopy as adjunct techniques for screening and predicting dementia due to Alzheimer's disease in clinical practice. ( Arai, H; Fujii, C; Hata, S; Higuchi, S; Igarashi, K; Ishii, R; Iwai, N; Moriya, M; Ohrui, T; Suzuki, T; Tokuda, T; Uemura, K; Waragai, M; Yoshida, M, 2014) |
| "Disease-specific metabolic changes in Alzheimer's disease and frontotemporal dementia/Pick complex were examined by proton magnetic resonance spectroscopy at 3." | 1.33 | Magnetic resonance spectroscopic study of Alzheimer's disease and frontotemporal dementia/Pick complex. ( Abe, K; Hattori, N; Mihara, M; Sakoda, S; Sawada, T, 2006) |
| "Choline (Cho)/Cr was higher than normal in patients with AD, FTLD, and DLB." | 1.32 | 1H MR spectroscopy in common dementias. ( Boeve, BF; Edland, SD; Ferman, TJ; Ivnik, RJ; Jack, CR; Kantarci, K; Knopman, DS; O'Brien, PC; Petersen, RC; Smith, GE; Tang-Wai, DF; Tangalos, EG; Weigand, SD, 2004) |
| "These observations suggest that in Alzheimer's disease there are no major changes in the extracellular concentrations of these putative amino acid transmitters." | 1.27 | Amino acid release from biopsy samples of temporal neocortex from patients with Alzheimer's disease. ( Bowen, DM; Davison, AN; Neary, D; Sims, NR; Smith, CC, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (12.24) | 18.7374 |
| 1990's | 8 (16.33) | 18.2507 |
| 2000's | 22 (44.90) | 29.6817 |
| 2010's | 13 (26.53) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Garringer, HJ | 1 |
| Murrell, J | 1 |
| Sammeta, N | 1 |
| Gnezda, A | 1 |
| Ghetti, B | 1 |
| Vidal, R | 1 |
| Kantarci, K | 4 |
| Targosz-Gajniak, MG | 1 |
| Siuda, JS | 1 |
| Wicher, MM | 1 |
| Banasik, TJ | 1 |
| Bujak, MA | 1 |
| Augusciak-Duma, AM | 1 |
| Opala, G | 1 |
| Waragai, M | 1 |
| Hata, S | 1 |
| Suzuki, T | 1 |
| Ishii, R | 1 |
| Fujii, C | 1 |
| Tokuda, T | 1 |
| Arai, H | 1 |
| Ohrui, T | 1 |
| Higuchi, S | 1 |
| Yoshida, M | 1 |
| Igarashi, K | 1 |
| Moriya, M | 1 |
| Iwai, N | 1 |
| Uemura, K | 1 |
| Tušková, R | 1 |
| Lipták, B | 1 |
| Szomolányi, P | 1 |
| Vančová, O | 1 |
| Uličná, O | 1 |
| Sumbalová, Z | 1 |
| Kucharská, J | 1 |
| Dubovický, M | 1 |
| Trattnig, S | 1 |
| Liptaj, T | 1 |
| Kašparová, S | 1 |
| Almuqbel, M | 1 |
| Melzer, TR | 1 |
| Myall, DJ | 1 |
| MacAskill, MR | 1 |
| Pitcher, TL | 1 |
| Livingston, L | 1 |
| Wood, KL | 1 |
| Keenan, RJ | 1 |
| Dalrymple-Alford, JC | 1 |
| Anderson, TJ | 1 |
| Ryu, B | 1 |
| Kawamata, T | 1 |
| Wakai, T | 1 |
| Shimizu, M | 1 |
| Yagi, S | 1 |
| Shimizu, T | 1 |
| Lin, AL | 1 |
| Powell, D | 1 |
| Caban-Holt, A | 1 |
| Jicha, G | 1 |
| Robertson, W | 1 |
| Gold, BT | 1 |
| Davis, R | 1 |
| Abner, E | 1 |
| Wilcock, DM | 1 |
| Schmitt, FA | 1 |
| Head, E | 1 |
| García Santos, JM | 1 |
| Gavrila, D | 1 |
| Antúnez, C | 1 |
| Tormo, MJ | 1 |
| Salmerón, D | 1 |
| Carles, R | 1 |
| Jiménez Veiga, J | 1 |
| Parrilla, G | 1 |
| Torres del Río, S | 1 |
| Fortuna, L | 1 |
| Navarro, C | 1 |
| Caserta, MT | 1 |
| Ragin, A | 1 |
| Hermida, AP | 1 |
| Ahrens, RJ | 1 |
| Wise, L | 1 |
| Weigand, SD | 2 |
| Przybelski, SA | 1 |
| Shiung, MM | 1 |
| Whitwell, JL | 1 |
| Negash, S | 1 |
| Knopman, DS | 2 |
| Boeve, BF | 2 |
| O'Brien, PC | 2 |
| Petersen, RC | 2 |
| Jack, CR | 2 |
| Pilatus, U | 1 |
| Lais, C | 1 |
| Rochmont, Adu M | 1 |
| Kratzsch, T | 1 |
| Frölich, L | 2 |
| Maurer, K | 1 |
| Zanella, FE | 1 |
| Lanfermann, H | 1 |
| Pantel, J | 1 |
| Parlayan, E | 1 |
| Yulug, B | 1 |
| Bakar, M | 1 |
| Gumustas, O | 1 |
| Hauser, T | 1 |
| Gerigk, L | 1 |
| Giesel, F | 1 |
| Schuster, L | 1 |
| Essig, M | 1 |
| Lamar, M | 1 |
| Foy, CML | 1 |
| Beacher, F | 1 |
| Daly, E | 1 |
| Poppe, M | 1 |
| Archer, N | 1 |
| Prasher, V | 1 |
| Murphy, KC | 1 |
| Morris, RG | 1 |
| Simmons, A | 1 |
| Lovestone, S | 1 |
| Murphy, DGM | 1 |
| Jessen, F | 1 |
| Lewczuk, P | 1 |
| Gür, O | 1 |
| Block, W | 1 |
| Ende, G | 1 |
| Hammen, T | 1 |
| Arlt, S | 1 |
| Kornhuber, J | 1 |
| Kucinski, T | 1 |
| Popp, J | 1 |
| Peters, O | 1 |
| Maier, W | 1 |
| Träber, F | 1 |
| Wiltfang, J | 1 |
| Pagonabarraga, J | 1 |
| Gómez-Ansón, B | 2 |
| Rotger, R | 1 |
| Llebaria, G | 1 |
| García-Sánchez, C | 1 |
| Pascual-Sedano, B | 1 |
| Gironell, A | 1 |
| Delfino, M | 1 |
| Ruscalleda, J | 1 |
| Kulisevsky, J | 1 |
| Weiss, U | 1 |
| Bacher, R | 1 |
| Vonbank, H | 1 |
| Kemmler, G | 1 |
| Lingg, A | 1 |
| Marksteiner, J | 1 |
| Kizu, O | 1 |
| Yamada, K | 1 |
| Ito, H | 1 |
| Nishimura, T | 1 |
| Tang-Wai, DF | 1 |
| Edland, SD | 1 |
| Smith, GE | 1 |
| Ivnik, RJ | 1 |
| Ferman, TJ | 1 |
| Tangalos, EG | 1 |
| Frederick, BD | 1 |
| Lyoo, IK | 1 |
| Satlin, A | 1 |
| Ahn, KH | 1 |
| Kim, MJ | 1 |
| Yurgelun-Todd, DA | 1 |
| Cohen, BM | 1 |
| Renshaw, PF | 1 |
| Chao, LL | 1 |
| Schuff, N | 2 |
| Kramer, JH | 1 |
| Du, AT | 1 |
| Capizzano, AA | 1 |
| O'Neill, J | 2 |
| Wolkowitz, OM | 1 |
| Jagust, WJ | 1 |
| Chui, HC | 1 |
| Miller, BL | 1 |
| Yaffe, K | 1 |
| Weiner, MW | 3 |
| Pfefferbaum, A | 1 |
| Adalsteinsson, E | 1 |
| Sullivan, EV | 1 |
| Metastasio, A | 1 |
| Rinaldi, P | 1 |
| Tarducci, R | 1 |
| Mariani, E | 1 |
| Feliziani, FT | 1 |
| Cherubini, A | 1 |
| Pelliccioli, GP | 1 |
| Gobbi, G | 1 |
| Senin, U | 1 |
| Mecocci, P | 1 |
| Mihara, M | 1 |
| Hattori, N | 1 |
| Abe, K | 1 |
| Sakoda, S | 1 |
| Sawada, T | 1 |
| Coulthard, E | 1 |
| Firbank, M | 1 |
| English, P | 1 |
| Welch, J | 1 |
| Birchall, D | 1 |
| O'Brien, J | 1 |
| Griffiths, TD | 1 |
| Mukherjee, O | 1 |
| Pastor, P | 1 |
| Cairns, NJ | 1 |
| Chakraverty, S | 1 |
| Kauwe, JS | 1 |
| Shears, S | 1 |
| Behrens, MI | 1 |
| Budde, J | 1 |
| Hinrichs, AL | 1 |
| Norton, J | 1 |
| Levitch, D | 1 |
| Taylor-Reinwald, L | 1 |
| Gitcho, M | 1 |
| Tu, PH | 1 |
| Tenenholz Grinberg, L | 1 |
| Liscic, RM | 1 |
| Armendariz, J | 1 |
| Morris, JC | 1 |
| Goate, AM | 1 |
| Garrard, P | 1 |
| Schott, JM | 1 |
| MacManus, DG | 1 |
| Hodges, JR | 1 |
| Fox, NC | 1 |
| Waldman, AD | 1 |
| Rami, L | 1 |
| Caprile, C | 1 |
| Sánchez-Valle, R | 1 |
| Monte, GC | 1 |
| Bosch, B | 1 |
| Molinuevo, JL | 1 |
| Xuan, X | 1 |
| Ding, M | 1 |
| Gong, X | 1 |
| Smith, CC | 2 |
| Bowen, DM | 3 |
| Sims, NR | 1 |
| Neary, D | 2 |
| Davison, AN | 1 |
| Tarbit, I | 1 |
| Perry, EK | 1 |
| Perry, RH | 1 |
| Blessed, G | 1 |
| Tomlinson, BE | 1 |
| Constans, JM | 1 |
| Meyerhoff, DJ | 1 |
| Gerson, J | 1 |
| MacKay, S | 1 |
| Norman, D | 1 |
| Fein, G | 1 |
| Shonk, T | 1 |
| Ross, BD | 2 |
| Shonk, TK | 1 |
| Moats, RA | 1 |
| Gifford, P | 1 |
| Michaelis, T | 1 |
| Mandigo, JC | 1 |
| Izumi, J | 1 |
| Bowen, BC | 1 |
| Block, RE | 1 |
| Sanchez-Ramos, J | 1 |
| Pattany, PM | 1 |
| Lampman, DA | 1 |
| Murdoch, JB | 1 |
| Quencer, RM | 1 |
| Holmes, C | 1 |
| Webster, MT | 1 |
| Procter, AW | 1 |
| Francis, PT | 2 |
| Shiino, A | 1 |
| Matsuda, M | 1 |
| Morikawa, S | 1 |
| Inubushi, T | 1 |
| Akiguchi, I | 1 |
| Handa, J | 1 |
| Ernst, T | 1 |
| Chang, L | 2 |
| Melchor, R | 1 |
| Mehringer, CM | 1 |
| Cheng, LL | 1 |
| Ma, MJ | 1 |
| Becerra, L | 1 |
| Ptak, T | 1 |
| Tracey, I | 1 |
| Lackner, A | 1 |
| González, RG | 1 |
| Eberling, JL | 1 |
| Jagust, W | 1 |
| Reed, B | 1 |
| Soto, G | 1 |
| Ezekiel, F | 1 |
| Klein, G | 1 |
| Inoue, T | 1 |
| Wang, F | 1 |
| Moriguchi, A | 1 |
| Shirakawa, K | 1 |
| Matsuoka, N | 1 |
| Goto, T | 1 |
| Harada, M | 1 |
| Miyoshi, H | 1 |
| Otsuka, H | 1 |
| Nishitani, H | 1 |
| Uno, M | 1 |
| Huang, W | 1 |
| Alexander, GE | 1 |
| Shetty, HU | 1 |
| Krasuski, JS | 1 |
| Rapoport, SI | 1 |
| Schapiro, MB | 1 |
| Kish, SJ | 1 |
| Chang, LJ | 1 |
| Mirchandani, L | 1 |
| Shannak, K | 1 |
| Hornykiewicz, O | 1 |
| Snowden, JS | 1 |
| Stone, TW | 1 |
| Connick, JH | 1 |
| Winn, P | 1 |
| Hastings, MH | 1 |
| English, M | 1 |
| Wilde, KM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open Label Study for the Use of Tyrosine Kinase Inhibitors for Treatment of Cognitive Decline Due to Degenerative Dementias[NCT02921477] | Phase 1 | 150 participants (Anticipated) | Interventional | 2016-09-30 | Enrolling by invitation | ||
| Focused Ultrasound Delivery of Exosomes for Treatment of Refractory Depression, Anxiety, and Neurodegenerative Dementias[NCT04202770] | 300 participants (Anticipated) | Interventional | 2019-12-01 | Suspended (stopped due to Pending COVID-19 pandemic; pending status of product development) | |||
| MRI Biomarkers of Risk in Sedentary and Exercise Trained Humans[NCT02729428] | 71 participants (Actual) | Observational | 2016-04-30 | Completed | |||
| An Open-label Exploratory Study With Memantine: Correlation Between Proton Magnetic Resonance Spectroscopy, Cerebrospinal Fluid Biomarkers, and Cognition in Patients With Mild to Moderate Alzheimer's Disease[NCT00551161] | Phase 4 | 12 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Ratios of myo-inositol (mI), N-acetylaspartate (NAA), total creatine (Cr), and choline (Cho) by single voxel 1H MRS (proton magnetic resonance spectroscopy). Mean (± SD) metabolite levels (normalized to T2-corrected water signal intensity) and metabolite ratios for Alzheimer's disease subjects at baseline (t0), after 24 weeks of ongoing monotherapy with stable-dose cholinesterase inhibitor (t1), and after another 24 weeks of combination therapy with memantine in addition to stable-dose cholinesterase inhibitor (t2). The Wilcoxon signed-rank test was used to examine whether the change between t0 and t1 differed from the change between t1 and t2 [(t2 - t1) - (t1 - t0)]. (NCT00551161)
Timeframe: Baseline, 24 weeks, and 48 weeks
| Intervention | ratio (normalized to T2-corrected water (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Change in NAA [(t2-t1) - (t1-t0)] | Change in Cr [(t2-t1) - (t1-t0)] | Change in Cho [(t2-t1) - (t1-t0)] | Change in mI [(t2-t1) - (t1-t0)] | Change in NAA/Cr [(t2-t1) - (t1-t0)] | Change in Cho/Cr [(t2-t1) - (t1-t0)] | Change in mI/Cr [(t2-t1) - (t1-t0)] | Change in NAA/Cho [(t2-t1) - (t1-t0)] | Change in NAA/mI [(t2-t1) - (t1-t0)] | |
| Memantine | -54 | -2 | 9 | 16 | -0.09 | 0.02 | 0.04 | -0.26 | -0.35 |
3 reviews available for aspartic acid and Dementia
| Article | Year |
|---|---|
Proton MRS in mild cognitive impairment.
Topics: Alzheimer Disease; Animals; Aspartic Acid; Biomarkers; Brain; Choline; Cognitive Dysfunction; Creati | 2013 |
Magnetic resonance spectroscopy in common dementias.
Topics: Aspartic Acid; Biomarkers; Brain; Dementia; Humans; Inositol; Magnetic Resonance Spectroscopy | 2013 |
Endogenous excitotoxic agents.
Topics: Animals; Aspartic Acid; Cell Survival; Central Nervous System; Dementia; Epilepsy; Glutamates; Gluta | 1987 |
2 trials available for aspartic acid and Dementia
| Article | Year |
|---|---|
Magnetic resonance spectroscopy performance for detection of dementia, Alzheimer's disease and mild cognitive impairment in a community-based survey.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Choline; Cognition Disorders; Crea | 2008 |
Probable Alzheimer disease: diagnosis with proton MR spectroscopy.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Brain Diseases, Metabolic; Creatine; Dementia; Diagno | 1995 |
44 other studies available for aspartic acid and Dementia
| Article | Year |
|---|---|
Increased tau phosphorylation and tau truncation, and decreased synaptophysin levels in mutant BRI2/tau transgenic mice.
Topics: Adaptor Proteins, Signal Transducing; Animals; Aspartic Acid; Cataract; Cerebellar Ataxia; Deafness; | 2013 |
Magnetic resonance spectroscopy as a predictor of conversion of mild cognitive impairment to dementia.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Brain; Choline; Cognitive Dysfunction; Creatine; Dementia; D | 2013 |
Magnetic resonance spectroscopy as a predictor of conversion of mild cognitive impairment to dementia.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Brain; Choline; Cognitive Dysfunction; Creatine; Dementia; D | 2013 |
Magnetic resonance spectroscopy as a predictor of conversion of mild cognitive impairment to dementia.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Brain; Choline; Cognitive Dysfunction; Creatine; Dementia; D | 2013 |
Magnetic resonance spectroscopy as a predictor of conversion of mild cognitive impairment to dementia.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Brain; Choline; Cognitive Dysfunction; Creatine; Dementia; D | 2013 |
Utility of SPM8 plus DARTEL (VSRAD) combined with magnetic resonance spectroscopy as adjunct techniques for screening and predicting dementia due to Alzheimer's disease in clinical practice.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Aspartic Acid; Brain; Choline; De | 2014 |
Neuronal marker recovery after Simvastatin treatment in dementia in the rat brain: in vivo magnetic resonance study.
Topics: Animals; Aspartic Acid; Biomarkers; Brain; Dementia; Dipeptides; Disease Models, Animal; Galactose; | 2015 |
Metabolite ratios in the posterior cingulate cortex do not track cognitive decline in Parkinson's disease in a clinical setting.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Bayes Theorem; Case-Control Studies; Choline; Cognitive Dysf | 2016 |
Reversible Cerebral Metabolism Changes Using Proton Magnetic Resonance Spectroscopy in a Patient with Intracranial Dural Arteriovenous Fistula: A Case Report.
Topics: Aged; Aspartic Acid; Central Nervous System Vascular Malformations; Coronary Angiography; Creatine; | 2016 |
(1)H-MRS metabolites in adults with Down syndrome: Effects of dementia.
Topics: Activities of Daily Living; Adult; Analysis of Variance; Aspartic Acid; Dementia; Down Syndrome; Fem | 2016 |
Single voxel magnetic resonance spectroscopy at 3 Tesla in a memory disorders clinic: early right hippocampal NAA/Cr loss in mildly impaired subjects.
Topics: Aged; Aspartic Acid; Choline; Creatine; Dementia; Female; Functional Laterality; Hippocampus; Humans | 2008 |
Risk of dementia in MCI: combined effect of cerebrovascular disease, volumetric MRI, and 1H MRS.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Atrophy; Biomarkers; Brain; Cerebrovascular Disorders; Cogni | 2009 |
Conversion to dementia in mild cognitive impairment is associated with decline of N-actylaspartate and creatine as revealed by magnetic resonance spectroscopy.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Choline; Cognition; Cognition Disorders; Creatine; De | 2009 |
Neurometabolic correlations of donepezil and rivastigmine in dementia patients: a different neuroprotective effect.
Topics: Aged; Aspartic Acid; Brain; Cognition Disorders; Dementia; Donepezil; Female; Humans; Indans; Magnet | 2009 |
[MR spectroscopy in dementia].
Topics: Aspartic Acid; Biomarkers; Brain; Creatinine; Dementia; Humans; Magnetic Resonance Spectroscopy; Oli | 2010 |
Down syndrome with and without dementia: an in vivo proton Magnetic Resonance Spectroscopy study with implications for Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain Chemistry; Case-Control Studies; Dementia; Down Syndro | 2011 |
Association of N-acetylaspartate and cerebrospinal fluid Aβ42 in dementia.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Aspartic Acid; Biomarkers; Cognitive Dysfunction; De | 2011 |
Spectroscopic changes associated with mild cognitive impairment and dementia in Parkinson's disease.
Topics: Aged, 80 and over; Aspartic Acid; Brain Chemistry; Cognition; Cognitive Dysfunction; Data Interpreta | 2012 |
Cognitive impairment: assessment with brain magnetic resonance imaging and proton magnetic resonance spectroscopy.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Brain Chemistry; Choline; Cognition Disorders; Creati | 2003 |
Posterior cingulate metabolic changes in frontotemporal lobar degeneration detected by magnetic resonance spectroscopy.
Topics: Adult; Aged; Alzheimer Disease; Aspartic Acid; Case-Control Studies; Choline; Creatine; Dementia; Di | 2004 |
1H MR spectroscopy in common dementias.
Topics: Acetylcholine; Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Brain Chemistry; Ch | 2004 |
In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Aspartic Acid; Brain Mapping; Case | 2004 |
Reduced medial temporal lobe N-acetylaspartate in cognitively impaired but nondemented patients.
Topics: Aged; Aspartic Acid; Atrophy; Cognition Disorders; Dementia; Female; Hippocampus; Humans; Magnetic R | 2005 |
Cortical NAA deficits in HIV infection without dementia: influence of alcoholism comorbidity.
Topics: Adult; Alcoholism; Aspartic Acid; Brain Mapping; Case-Control Studies; Cerebral Cortex; Choline; Com | 2005 |
Conversion of MCI to dementia: Role of proton magnetic resonance spectroscopy.
Topics: Aged; Amnesia; Aspartic Acid; Cerebral Cortex; Choline; Cognition Disorders; Creatine; Dementia; Dis | 2006 |
Magnetic resonance spectroscopic study of Alzheimer's disease and frontotemporal dementia/Pick complex.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain Mapping; Cerebral Cortex; Creatine; Dementia; Down-Reg | 2006 |
Proton magnetic resonance spectroscopy in frontotemporal dementia.
Topics: Aged; Aspartic Acid; Biomarkers; Cerebral Cortex; Dementia; Female; Frontal Lobe; Gliosis; Gyrus Cin | 2006 |
HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin-positive, tau-negative inclusions caused by a missense mutation in the signal peptide of progranulin.
Topics: Adult; Aged; Aged, 80 and over; Aspartic Acid; Chromosomes, Human, Pair 17; Dementia; DNA Mutational | 2006 |
Posterior cingulate neurometabolite profiles and clinical phenotype in frontotemporal dementia.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Atrophy; Dementia; Diagnosis, Differential; Female; Frontal | 2006 |
Naming is associated with left temporal pole metabolite levels in neurodegenerative diseases.
Topics: Aged; Amnesia; Anomia; Aspartic Acid; Choline; Cognition Disorders; Creatine; Dementia; Female; Huma | 2008 |
Proton magnetic resonance spectroscopy detects a relative decrease of N-acetylaspartate in the hippocampus of patients with dementia with Lewy bodies.
Topics: Aged; Aspartic Acid; Chi-Square Distribution; Choline; Creatine; Dementia; Female; Hippocampus; Huma | 2008 |
Amino acid release from biopsy samples of temporal neocortex from patients with Alzheimer's disease.
Topics: Acetylcholine; Alzheimer Disease; Amino Acids; Aspartic Acid; Dementia; gamma-Aminobutyric Acid; Glu | 1983 |
Hippocampal free amino acids in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Amino Acids; Arginine; Aspartic Acid; Dementia; gamma-Aminobutyric Acid; Gl | 1980 |
H-1 MR spectroscopic imaging of white matter signal hyperintensities: Alzheimer disease and ischemic vascular dementia.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Brain Diseases; Brain Ischemia; Case-Control Studies; | 1995 |
Role of increased cerebral myo-inositol in the dementia of Down syndrome.
Topics: Adolescent; Adult; Alzheimer Disease; Aspartic Acid; Brain; Child; Child, Preschool; Choline; Creati | 1995 |
Proton MR spectroscopy of the brain in 14 patients with Parkinson disease.
Topics: Adult; Aged; Aged, 80 and over; Aspartic Acid; Brain; Choline; Creatine; Dementia; Energy Metabolism | 1995 |
Relationship between beta-amyloid precursor protein, pyramidal neurones and astrocytes in human neocortex.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Antibodies, Monoclonal; Aspartic Acid; Biological | 1993 |
Proton magnetic resonance spectroscopy with dementia.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Creatine; Dementia; Female; Humans | 1993 |
Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Dementia; Discriminant Analysis; Female; | 1997 |
Quantitative neuropathology by high resolution magic angle spinning proton magnetic resonance spectroscopy.
Topics: Amino Acids; Animals; Aspartic Acid; Biomarkers; Brain; Cerebral Cortex; Dementia; Haplorhini; Human | 1997 |
Method to correlate 1H MRSI and 18FDG-PET.
Topics: Aged; Algorithms; Analysis of Variance; Aspartic Acid; Brain; Cognition Disorders; Dementia; Female; | 2000 |
FK960, a novel potential anti-dementia drug, enhances high K(+)-evoked release of somatostatin from rat hippocampal slices.
Topics: Acetylcholine; Animals; Aspartic Acid; Benzamides; Dementia; gamma-Aminobutyric Acid; Hippocampus; I | 2001 |
Multivariate analysis of regional metabolic differences in normal ageing on localised quantitative proton MR spectroscopy.
Topics: Adult; Aged; Aging; Aspartic Acid; Cerebrospinal Fluid; Corpus Striatum; Dementia; Female; Frontal L | 2001 |
Brain metabolite concentration and dementia severity in Alzheimer's disease: a (1)H MRS study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Aspartic Acid; Brain; Choline; Cre | 2001 |
Progressive supranuclear palsy: relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers.
Topics: Aged; Aspartic Acid; Basal Ganglia Diseases; Brain; Bulbar Palsy, Progressive; Choline O-Acetyltrans | 1985 |
Putative amino acid transmitters in lumbar cerebrospinal fluid of patients with histologically verified Alzheimer's dementia.
Topics: Adult; Aged; Alzheimer Disease; Amino Acids; Aspartic Acid; Dementia; Epilepsy; Female; Glutamates; | 1985 |
[Comments on a geriatric drug].
Topics: Aged; Asparagine; Aspartic Acid; Dementia; Drug Combinations; Female; Hematoporphyrins; Humans; Magn | 1974 |